Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies

Clinical trial NCT05690581 · RECRUITING

Trial details

NCT number: NCT05690581
Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumors and Hematologic Malignancies

Start date: 2023-02-23
Primary completion: 2025-10-30
Enrollment: 146

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.